By Sneha S K June 6 (Reuters) - Medical device maker Dexcom said the use of its continuous glucose monitor, G7, led to ...

Results from the 2021 MOBILE study, sponsored by Dexcom and using Dexcom CGM, served as the primary piece of clinical evidence that led to this coverage expansion by demonstrating that CGM use ...

DexCom (NASDAQ:DXCM) used its 2026 Investor Day to outline a long-range plan centered on new product launches, broader insurance coverage for continuous glucose monitoring, international expansion and ...

BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, announced today that its latest ...

DexCom Inc. DXCM recently announced that its G7 Continuous Glucose Monitoring (CGM) System will be added to the Régie de l'assurance maladie du Québec (RAMQ) Public Prescription Drug Insurance Plan.